All In Biotech

NDA 021773 · Astrazeneca Ab

Byetta

Exenatide Synthetic · Subcutaneous · GLP-1 Receptor Agonist

NovelDiscontinued

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Apr 28, 2005

Approved uses

6

Original approval plus efficacy supplements

Registered trials

302

90 Phase 3, 8 recruiting

FAERS reports

52,320

14,635 serious, 1,764 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2025.

BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use • Coadministration with other exenatide-containing products is not recommended ( 1 ).

Mechanism: Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind and activate the human GLP-1 receptor in vitro . This leads to an increase in both...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BYETTA · EXENATIDE SYNTHETIC 300MCG/1.2ML (250MCG/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued · TE AP
  • BYETTA · EXENATIDE SYNTHETIC 600MCG/2.4ML (250MCG/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Exenatide Synthetic" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased15,472
  • weight decreased12,126
  • nausea12,042
  • decreased appetite5,643
  • blood glucose decreased5,516
  • vomiting4,346
  • diarrhoea2,742
  • dizziness2,674
  • drug ineffective2,251
  • headache2,087
  • injection site pain2,023
  • pancreatitis2,011

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051,970
200612,666
200712,432
20087,681
20092,461
20101,753
20111,820
2012996
20131,460
20141,912
20152,516
20161,149
2017892
2018771
2019642
2020340
2021274
2022197
2023127
2024169
202575
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Byetta (Exenatide)

2024 spending

$15.9M

Beneficiaries

3,043

11,712 claims

Per beneficiary

$5,218

$459.82 per unit

View as table
YearSpending
2020$47,676,632
2021$37,988,662
2022$27,500,961
2023$20,645,626
2024$15,877,480

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.